Tampa healthcare company cuts management positions, shifts focus

A Tampa healthcare technology and pharmaceutical distribution company is reducing corporate management positions and redirecting workforce spending to a new cancer diagnostic test as it works to build up business at a newly acquired laboratory. 

DataMeds AI Inc., a publicly traded healthcare company that also operates under the name DataMeds SI, announced Tuesday it would be enforcing “cost controls” to refocus its remaining workforce and available funding on commercializing ChemoFx. That’s a laboratory test designed to help oncologists choose the right chemotherapy regimens for patients, initially for gynecological cancers only. 

Image courtesy of DataMeds AI

The company did not disclose how many positions were eliminated, the anticipated savings or the remaining employee count. DataMeds AI reported $23.34 million in revenue for the 2025 fiscal year, a nearly 29% increase over its $18.13 million revenue reported in the 2024 fiscal year.

The announcement comes about one month after DataMeds acquired Helomics, a precision oncology and AI-driven cancer diagnostics company based in Pittsburgh, from AI infrastructure provider Axe Compute. DataMeds valued the stock-and-note transaction at $1.5 million and said the acquisition included laboratory equipment, a contract research business and about $1.5 million in cash. That deal closed Sept. 11, according to the Securities and Exchange Commission filing, and also included Helomics’ Predictive Oncology Cancer Biomarker Super Intelligence (SI) division.

ChemoFX, meanwhile, tests a patient’s live cancer cells outside the body against a panel of different chemotherapy drugs, providing oncologists with data on how a patient’s specific tumor cells respond to different treatments. 

The test has yet to be cleared or approved by the U.S. Food and Drug Administration, DataMeds says, but has recently been included for the first time in a Humana Medicaid coverage policy for gynecologic cancers. It has been commercially available in the U.S. since 1997, DataMeds says. 

“Leveraging DataMEDS’ management team's deep relationships in oncology, we are preparing to relaunch a marketing campaign for ChemoFx,” interim co-CEO Gerald Commissiong says in the release.

DataMeds has already begun discussions with hospital systems, health maintenance organizations, group purchasing organizations and specialty cancer centers about adding the test to their cancer testing programs, Commissiong says in the release.